Julia Teixeira Cottas de Azevedo

Julia Teixeira Cottas de Azevedo

Auto-generated profile, based on publicly available information

Julia Teixeira Cottas de Azevedo

Department of Hemotherapy and Cell Therapy, Einstein Hospital Israelita, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Cytotherapy
Verified
Journal Article
Open access
ABAlison Felipe Bordini Biggi
Alison Felipe Bordini Biggi
RSRenata Nacasaki Silvestre
Renata Nacasaki Silvestre
MTMariane Cariati Tirapelle
Mariane Cariati Tirapelle
JAJulia Teixeira Cottas de Azevedo
Julia Teixeira Cottas de Azevedo
HGHenry David Mogollón García
Henry David Mogollón García
VPVirginia Picanço-Castro
Virginia Picanço-Castro
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells has shown promising results in early-phase clinical studies. However, advancing CAR-NK cell therapeutic efficacy is imperative. In this study, we investigated the impact of a fourth-generation CD19-targeted CAR (CAR.19) coexpressing IL-27 on NK-92 cells. We observed a significant improvement in NK-92 cell proliferation and cytotoxicity activity against B-cell cancer cell lines, both in vitro and in a xenograft mouse B-cell lymphoma model. Our systematic transcriptome analysis of the activated NK-92 CAR variants further supports the potential of IL-27 in fourth-generation CARs to overcome limitations of NK cell-based targeted tumor therapies by providing essential growth and activation signals. Integrating IL-27 into CAR-NK cells emerges as a promising strategy to enhance their therapeutic potential and elicit robust responses against cancer cells. These findings contribute substantially to the mounting evidence supporting the potential of fourth-generation CAR engineering in advancing NK cell-based immunotherapies.

13 November 2024 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
JAJúlia Teixeira Cottas de Azevedo
Júlia Teixeira Cottas de Azevedo
JGJuliana Aparecida Preto de Godoy
Juliana Aparecida Preto de Godoy
CSCláudia de Souza
Cláudia de Souza
MSMicheli Severo Sielski
Micheli Severo Sielski
LCLarissa Leggieri Coa
Larissa Leggieri Coa
RPRaquel de Melo Alves Paiva
Raquel de Melo Alves Paiva
Natural Killer cells are immune leukocytes required for responses against tumor cells and virus-infected cells. In the last decade, natural killer cells have emerged as promising tools in cancer therapy, and clinical studies on patients treated with natural killer cells have revealed increased rates of disease-free survival. In this article, we review results from the major clinical trials that have used natural killer cells for cancer treatment, including their global distribution. We also discuss the major mechanisms of natural

5 February 2026 in Cytotherapy
Verified
Journal Article
Closed access
RARaquel de Melo Alves-Paiva
Raquel de Melo Alves-Paiva
LCLarissa L. Coa
Larissa L. Coa
JAJulia T. Azevedo
Julia T. Azevedo
JSJamile Ramos da Silva
Jamile Ramos da Silva
JGJuliana A. P de Godoy
Juliana A. P de Godoy
LKLucila N. Kerbauy
Lucila N. Kerbauy